Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2012, Article ID 407171, 12 pages
http://dx.doi.org/10.1155/2012/407171
Review Article

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

Département de Psychiatrie, Université de Montréal, Montréal, Québec, 2900, Canada

Received 23 October 2011; Accepted 21 November 2011

Academic Editor: Robin A. Emsley

Copyright © 2012 Simon Zhornitsky and Emmanuel Stip. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Stahl, Essential Psychopharmacology, Cambridge University Press, New York, NY, USA, 2nd edition, 2005.
  2. W. W. Eaton, S. S. Martins, G. Nestadt, O. J. Bienvenu, D. Clarke, and P. Alexandre, “The burden of mental disorders,” Epidemiologic Reviews, vol. 30, no. 1, pp. 1–14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Tandon, H. A. Nasrallah, and M. S. Keshavan, “Schizophrenia, “just the facts” 4. Clinical features and conceptualization,” Schizophrenia Research, vol. 110, no. 1–3, pp. 1–23, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. R. J. Wyat, “Neuroleptics and the natural course of schizophrenia,” Schizophrenia Bulletin, vol. 17, no. 2, pp. 325–351, 1991. View at Google Scholar · View at Scopus
  5. R. de Bont, “Schizophrenia, evolution and the borders of biology: on Huxley et al.'s 1964 paper in Nature,” History of Psychiatry, vol. 21, no. 2, pp. 144–159, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. T. J. Crow, J. F. MacMillan, A. L. Johnson, and E. C. Johnstone, “II. A randomized controlled trial of prophylactic neuroleptic treatment,” British Journal of Psychiatry, vol. 148, pp. 120–127, 1986. View at Google Scholar · View at Scopus
  7. M. Harrow, T. H. Jobe, L. S. Grossman, V. Ghogari, and R. N. Faull, “Lifetime antipsychotic treatment for all schizophrenia patients? A 26-year evidence-based approach,” Schizophrenia Bulletin, vol. 37, no. s1, pp. 1–342, 2011. View at Google Scholar
  8. P. R. May, Treatment of Schizophrenia: A Comparative Study of Five Treatment Methods, Science House, New York, NY, USA, 1968.
  9. J. Tiihonen, J. Haukka, M. Taylor, P. M. Haddad, M. X. Patel, and P. Korhonen, “A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia,” American Journal of Psychiatry, vol. 168, no. 6, pp. 603–609, 2011. View at Publisher · View at Google Scholar
  10. B. J. Miller, “A review of second-generation antipsychotic discontinuation in first-episode psychosis,” Journal of Psychiatric Practice, vol. 14, no. 5, pp. 289–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Guevremont, J. Sablier, P. Vincent et al., “DoPill, an electronic pill dispenser, helping control medication adherence in patients with schizophrenia,” International Clinical Psychopharmacology, vol. 26, p. e83, 2011. View at Publisher · View at Google Scholar
  12. E. Stip, A. Abdel-Baki, D. Bloom, S. Grignon, and M.-A. Roy, “An expert opinion from the Association des médecins psychiatres du Québec,” Canadian Journal of Psychiatry, vol. 56, no. 6, pp. 367–376, 2011. View at Google Scholar
  13. E. Stip, “Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry,” Encephale, supplement 3, pp. S115–S118, 2009. View at Google Scholar
  14. J. M. Kane and C. Garcia-Ribera, “Clinical guideline recommendations for antipsychotic long-acting injections,” British Journal of Psychiatry, vol. 195, no. 52, pp. s63–s67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. D. A. Johnson and H. Freeman, “Drug defaulting by patients on long-acting phenothiazines,” Psychological Medicine, vol. 3, no. 1, pp. 115–119, 1973. View at Google Scholar · View at Scopus
  16. D. A. Hughes, “Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens,” British Journal of Clinical Pharmacology, vol. 65, no. 6, pp. 871–878, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Ereshefsky and C. A. Mascarenas, “Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics,” Journal of Clinical Psychiatry, vol. 64, no. 16, pp. 18–23, 2003. View at Google Scholar · View at Scopus
  18. W. W. Fleischhacker, U. Meise, V. Gunther, and M. Kurz, “Compliance with antipsychotic drug treatment: influence of side effects,” Acta Psychiatrica Scandinavica, vol. 89, no. 382, pp. 11–15, 1994. View at Google Scholar · View at Scopus
  19. J. M. Davis, L. Metalon, M. D. Watanabe, and L. Blake, “Depot antipsychotic drugs. Place in therapy,” Drugs, vol. 47, no. 5, pp. 741–773, 1994. View at Google Scholar · View at Scopus
  20. Y. Bloch, S. Mendlovic, S. Strupinsky, A. Altshuler, S. Fennig, and G. Ratzoni, “Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?” Journal of Clinical Psychiatry, vol. 62, no. 11, pp. 855–859, 2001. View at Google Scholar · View at Scopus
  21. J. Hay, “Complications at site of injection of depot neuroleptics,” British Medical Journal, vol. 311, no. 7002, p. 421, 1995. View at Google Scholar · View at Scopus
  22. G. L. Hamann, T. M. Egan, B. G. Wells, and J. E. Grimmig, “Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL,” Journal of Clinical Psychiatry, vol. 51, no. 12, pp. 502–504, 1990. View at Google Scholar · View at Scopus
  23. H. Li, Q. Rui, X. Ning, H. Xu, and N. Gu, “A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 35, no. 4, pp. 1002–1008, 2011. View at Publisher · View at Google Scholar
  24. J. P. Lindenmayer, “Long-acting injectable antipsychotics: focus on olanzapine pamoate,” Journal of Neuropsychiatric Disease and Treatment, vol. 24, pp. 261–267, 2010. View at Google Scholar
  25. J. M. Kane, H. C. Detke, D. Naber et al., “Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia,” American Journal of Psychiatry, vol. 167, no. 2, pp. 181–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Chue, M. Eerdekens, I. Augustyns et al., “Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets,” European Neuropsychopharmacology, vol. 15, no. 1, pp. 111–117, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Lindenmayer, K. Jarboe, C. A. Bossie, Y. Zhu, A. Mehnert, and R. Lasser, “Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone,” International Clinical Psychopharmacology, vol. 20, no. 4, pp. 213–221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Ereshefsky, S. R. Saklad, and M. W. Jann, “Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches,” Journal of Clinical Psychiatry, vol. 45, no. 5 II, pp. 50–59, 1984. View at Google Scholar
  29. M. W. Jann, L. Ereshefsky, and S. R. Saklad, “Clinical pharmacokinetics of the depot antipsychotics,” Clinical Pharmacokinetics, vol. 10, no. 4, pp. 315–333, 1985. View at Google Scholar · View at Scopus
  30. F. Jouen, P. Verite, D. Andre, L. Colonna, and P. Boucly, “Plasma fluphenazine levels measured by high-performance liquid chromatography in patients treated with depot injections,” Arzneimittel-Forschung/Drug Research, vol. 43, no. 5, pp. 509–511, 1993. View at Google Scholar · View at Scopus
  31. S. J. Keith, J. M. Kane, M. Turner, R. R. Conley, and H. A. Nasrallah, “Guidelines for the use of long-acting injectable atypical antipsychotics,” Journal of Clinical Psychiatry, vol. 65, no. 1, pp. 120–130, 2004. View at Publisher · View at Google Scholar
  32. D. A. W. Johnson, “The side effects of fluphenazine decanoate,” British Journal of Psychiatry, vol. 122, no. 576, pp. 519–522, 1973. View at Google Scholar · View at Scopus
  33. S. H. Curry, A. C. Altamura, and S. Montgomery, “Unwanted effects of fluphenazine enanthate and decanoate,” The Lancet, vol. 1, no. 8111, pp. 331–332, 1979. View at Google Scholar · View at Scopus
  34. M. J. Gitlin, K. H. Nuechterlein, J. Mintz et al., “Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression,” Psychopharmacology, vol. 148, no. 4, pp. 350–354, 2000. View at Google Scholar · View at Scopus
  35. T. L. Purvis, R. N. Hieber, T. Dellenbaugh, and R. W. Sommi, “Pharmacokinetics of the long-acting, first-generation antipsychotic fluphenazine,” Pharmacotherapy, vol. 31, no. 4, article 438, pp. 71e–75e, 2011. View at Publisher · View at Google Scholar
  36. B. Wistedt, D. Wiles, and T. Kolakowska, “Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics,” The Lancet, vol. 1, no. 8230, p. 1163, 1981. View at Google Scholar · View at Scopus
  37. R. C. Love and R. J. Conley, “Long-acting risperidone injection,” American Journal of Health-System Pharmacy, vol. 61, no. 17, pp. 1792–1800, 2004. View at Google Scholar · View at Scopus
  38. R. T. Owen, “Paliperidone palmitate injection: its efficacy, safety and tolerability in schizophrenia,” Drugs of Today, vol. 46, no. 7, pp. 463–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. R. A. Rosenheck, J. H. Krystal, R. Lew et al., “Long-acting risperidone and oral antipsychotics in unstable schizophrenia,” New England Journal of Medicine, vol. 364, no. 9, pp. 842–851, 2011. View at Publisher · View at Google Scholar
  40. Ortho Janssen, “An open-label randomized trial comparing Risperdal Consta with oral antipsychotic care in the treatment of early psychosis,” CR005959, http://download.veritasmedicine.com/PDF/CR005959_CSR_synopsis.pdf.
  41. C. E. Adams, M. K. P. Fenton, S. Quraishi, and A. S. David, “Systematic meta-review of depot antipsychotic drugs for people with schizophrenia,” British Journal of Psychiatry, vol. 179, pp. 290–299, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. J. R. Vittengl, “Temporal regularities in physical control at a state psychiatric hospital,” Archives of Psychiatric Nursing, vol. 16, no. 2, pp. 80–85, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. C. Leucht, S. Heres, J. M. Kane, W. Kissling, J. M. Davis, and S. Leucht, “Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials,” Schizophrenia Research, vol. 127, no. 1–3, pp. 83–92, 2011. View at Publisher · View at Google Scholar
  44. R. S. Kahn, W. W. Fleischhacker, H. Boter et al., “Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial,” The Lancet, vol. 371, no. 9618, pp. 1085–1097, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Komossa, C. Rummel-Kluge, F. Schmid et al., “Quetiapine versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews, vol. 20, no. 1, article CD006625, 2010. View at Google Scholar · View at Scopus
  46. S. Zhornitsky, S. Potvin, H. Moteshafi, S. Dubreucq, P.-P. Rompré, and E. Stip, “Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials,” International Clinical Psychopharmacology, vol. 26, no. 4, pp. 183–192, 2011. View at Publisher · View at Google Scholar
  47. A. W. Zuardi, A. C. Giampietro, and E. R. Grassi, “Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients,” Current Therapeutic Research, vol. 34, no. 2 I, pp. 253–261, 1983. View at Google Scholar
  48. J. Kinross-Wright and K. D. Charalampous, “A controlled study of a very long-acting phenothiazine preparation,” International Journal of Neuropsychiatry, vol. 1, pp. 66–70, 1964. View at Google Scholar
  49. C. L. Ravaris, L. A. Weaver, and G. W. Brooks, “A controlled study of fluphenazine enanthate in chronic schizophrenic patients,” Diseases of the Nervous System, vol. 26, pp. 33–39, 1965. View at Google Scholar · View at Scopus
  50. I. Haider, “A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics,” British Journal of Psychiatry, vol. 114, no. 512, pp. 837–841, 1968. View at Google Scholar · View at Scopus
  51. H. M. van Praag, J. Breetveld, H. van Mesdag-Etty, R. Westerhuis, A. Pen, and T. Schut, “A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients,” Psychiatria, Neurologia, Neurochirurgia, vol. 73, no. 3, pp. 165–175, 1970. View at Google Scholar · View at Scopus
  52. J. Del Giudice, W. G. Clark, and E. F. Gocka, “Prevention of recidivism of schizophrenics treated with fluphenazine enanthate,” Psychosomatics, vol. 16, no. 1, pp. 32–36, 1975. View at Google Scholar · View at Scopus
  53. A. Rifkin, F. Quitkin, C. J. Rabiner, and D. F. Klein, “Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year,” Archives of General Psychiatry, vol. 34, no. 1, pp. 43–47, 1977. View at Google Scholar · View at Scopus
  54. G. E. Hogarty, N. R. Schooler, and R. Ulrich, “Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride,” Archives of General Psychiatry, vol. 36, no. 12, pp. 1283–1294, 1979. View at Google Scholar
  55. N. R. Schooler, J. Levine, and J. B. Severe, “Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate,” Archives of General Psychiatry, vol. 37, no. 1, pp. 16–24, 1980. View at Google Scholar
  56. C. Arango, I. Bombín, T. González-Salvador, I. García-Cabeza, and J. Bobes, “Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence,” European Psychiatry, vol. 21, no. 1, pp. 34–40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. M. Bai, T. T. Chen, J. Y. Chen et al., “Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study,” Journal of Clinical Psychiatry, vol. 68, no. 8, pp. 1218–1225, 2007. View at Google Scholar · View at Scopus
  58. E. Lily and Company, “Olanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia,” NCT00320489, 2010.
  59. B. Zhu, H. Ascher-Svanum, L. Shi, D. Faries, W. Montgomery, and S. R. Marder, “Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia,” Psychiatric Services, vol. 59, no. 3, pp. 315–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. B. Kim, S. H. Lee, T. K. Choi et al., “Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 5, pp. 1231–1235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Tiihonen, K. Wahlbeck, J. Lönnqvist et al., “Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study,” British Medical Journal, vol. 333, no. 7561, pp. 224–227, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. A. C. Altamura, S. H. Curry, S. Montgomery, and D. H. Wiles, “Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients,” Psychopharmacology, vol. 87, no. 1, pp. 30–33, 1985. View at Google Scholar · View at Scopus
  63. A. Rifkin, F. Quitkin, and D. F. Klein, “Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data,” Archives of General Psychiatry, vol. 34, no. 10, pp. 1215–1219, 1977. View at Google Scholar · View at Scopus
  64. K. K. Midha, J. W. Hubbard, S. R. Marder, B. D. Marshall, and T. Van Putten, “Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 19, no. 4, pp. 254–264, 1994. View at Google Scholar · View at Scopus
  65. R. Nesvåg, M. Hendset, H. Refsum, and L. Tanum, “Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication,” Acta Psychiatrica Scandinavica, vol. 114, no. 1, pp. 21–26, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. I. Castberg and O. Spigset, “Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service,” Therapeutic Drug Monitoring, vol. 27, no. 1, pp. 103–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. J. E. Leysen, P. M. F. Janssen, A. A. H. P. Megens, and A. Schotte, “Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity,” Journal of Clinical Psychiatry, vol. 55, no. 5, pp. 5–12, 1994. View at Google Scholar · View at Scopus
  68. D. A. Regier, M. E. Farmer, D. S. Rae et al., “Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study,” Journal of the American Medical Association, vol. 264, no. 19, pp. 2511–2518, 1990. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Opsal, T. Clausen, O. Kristensen, I. Elvik, I. Joa, and T. K. Larsen, “Involuntary hospitalization of first-episode psychosis with substance abuse during a 2-year follow-up,” Acta Psychiatrica Scandinavica, vol. 124, no. 3, pp. 198–204, 2011. View at Publisher · View at Google Scholar
  70. S. Zhornitsky, E. Stip, T. Pampoulova et al., “Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia,” Movement Disorders, vol. 25, no. 13, pp. 2188–2194, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. K. T. Mueser, R. E. Drake, and M. A. Wallach, “Dual diagnosis: a review of etiological theories,” Addictive Behaviors, vol. 23, no. 6, pp. 717–734, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. J. C. Negrete, “Clinical aspects of substance abuse in persons with schizophrenia,” Canadian Journal of Psychiatry, vol. 48, no. 1, pp. 14–21, 2003. View at Google Scholar · View at Scopus
  73. M. Valenstein, D. Ganoczy, J. F. McCarthy, H. M. Kim, T. A. Lee, and F. C. Blow, “Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review,” Journal of Clinical Psychiatry, vol. 67, no. 10, pp. 1542–1550, 2006. View at Google Scholar · View at Scopus
  74. G. Rubio, I. Martínez, G. Ponce, M. A. Jiménez-Arriero, F. López-Muñoz, and C. Álamo, “Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity,” Canadian Journal of Psychiatry, vol. 51, no. 8, pp. 531–539, 2006. View at Google Scholar · View at Scopus
  75. E. B. Stuyt, T. A. Sajbel, and M. H. Allen, “Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders,” American Journal on Addictions, vol. 15, no. 2, pp. 166–173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. M. L. Dahl, “Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?” Clinical Pharmacokinetics, vol. 41, no. 7, pp. 453–470, 2002. View at Google Scholar · View at Scopus
  77. L. Ereshefsky, S. R. Saklad, M. D. Watanabe, C. M. Davis, and M. W. Jann, “Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables,” Journal of Clinical Psychopharmacology, vol. 11, no. 5, pp. 296–301, 1991. View at Google Scholar · View at Scopus
  78. G. A. Wiesbeck, H. G. Weijers, O. M. Lesch, T. Glaser, P. J. Toennes, and J. Boening, “Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study,” Alcohol and Alcoholism, vol. 36, no. 4, pp. 329–334, 2001. View at Google Scholar · View at Scopus
  79. T. Loebl, G. A. Angarita, G. N. Pachas et al., “A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men,” Journal of Clinical Psychiatry, vol. 69, no. 3, pp. 480–486, 2008. View at Google Scholar · View at Scopus
  80. F. H. Gawin, M. E. Khalsa-Denison, and P. Jatlow, “Flupenthixol and desipramine treatment of crack users: double blind results,” European Neuropsychopharmacology, vol. 6, pp. 120–121, 1996. View at Google Scholar
  81. F. H. Gawin, M. E. Khalsa-Denison, and P. Jatlow, “Flupentixol-induced aversion to crack cocaine,” New England Journal of Medicine, vol. 334, no. 20, pp. 1340–1341, 1996. View at Publisher · View at Google Scholar · View at Scopus
  82. S. M. Evans, S. L. Walsh, F. R. Levin, R. W. Foltin, M. W. Fischman, and G. E. Bigelow, “Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans,” Drug and Alcohol Dependence, vol. 64, no. 3, pp. 271–283, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. A. N. Samaha, P. Seeman, J. Stewart, H. Rajabi, and S. Kapur, “"Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time,” Journal of Neuroscience, vol. 27, no. 11, pp. 2979–2986, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. S. R. Marder, T. V. Putten, M. Aravagiri et al., “Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine,” Psychopharmacology Bulletin, vol. 25, no. 3, pp. 479–482, 1989. View at Google Scholar · View at Scopus
  85. S. Nyberg, L. Farde, and C. Halldin, “Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate: preliminary findings,” Archives of General Psychiatry, vol. 54, no. 10, pp. 953–958, 1997. View at Google Scholar · View at Scopus
  86. M. Olfson, S. C. Marcus, and H. Ascher-Svanum, “Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone,” Schizophrenia Bulletin, vol. 33, no. 6, pp. 1379–1387, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. M. H. Trudeau, M. A. Bruneau, E. Stip, F. Grünberg, and M. Boivin, “Categorical refusal of treatment by psychiatric patients: balance, survey and prospects,” Canadian Journal of Psychiatry, vol. 44, pp. 583–588, 1999. View at Google Scholar
  88. K. Vaughan, N. McConaghy, C. Wolf, C. Myhr, and T. Black, “Community Treatment Orders: relationship to clinical care, medication compliance, behavioural disturbance and readmission,” Australian and New Zealand Journal of Psychiatry, vol. 34, no. 5, pp. 801–808, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Muirhead, C. Harvey, and G. Ingram, “Effectiveness of community treatment orders for treatment of schizophrenia with oral or depot antipsychotic medication: clinical outcomes,” Australian and New Zealand Journal of Psychiatry, vol. 40, no. 6-7, pp. 596–605, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. M. S. Swartz, J. W. Swanson, H. R. Wagner, B. J. Burns, and V. A. Hiday, “Effects of involuntary outpatient commitment and depot antipsychotics on treatment adherence in persons with severe mental illness,” Journal of Nervous and Mental Disease, vol. 189, no. 9, pp. 583–592, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. J. M. Kane, A. Rifkin, and M. Woerner, “Low-dose neuroleptic treatment of outpatient schizophrenics I. Preliminary results for relapse rates,” Archives of General Psychiatry, vol. 40, no. 8, pp. 893–896, 1983. View at Google Scholar
  92. S. R. Marder, T. Van Putten, and J. Mintz, “Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome,” Archives of General Psychiatry, vol. 44, no. 6, pp. 518–521, 1987. View at Google Scholar
  93. H. A. McClelland, R. G. Farquharson, and P. Leyburn, “Very high dose fluphenazine decanoate. A controlled trial in chronic schizphrenia,” Archives of General Psychiatry, vol. 33, no. 12, pp. 1435–1439, 1976. View at Google Scholar
  94. W. Kissling, Guidelines for Neuroleptic Relapse Prevention in Schizophrenia, Springer, 1991.
  95. D. A. W. Johnson, “Historical perspective on antipsychotic long-acting injections,” British Journal of Psychiatry, vol. 195, no. 52, pp. s7–s12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. G. E. Hogarty and R. F. Ulrich, “The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment,” Journal of Psychiatric Research, vol. 32, no. 3-4, pp. 243–250, 1998. View at Publisher · View at Google Scholar · View at Scopus